HomeCompareAVRO vs EPRT

AVRO vs EPRT: Dividend Comparison 2026

AVRO yields 142.86% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AVRO wins by $19.49M in total portfolio value
10 years
AVRO
AVRO
● Live price
142.86%
Share price
$1.40
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19.55M
Annual income
$8,225,014.26
Full AVRO calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — AVRO vs EPRT

📍 AVRO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAVROEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AVRO + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AVRO pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AVRO
Annual income on $10K today (after 15% tax)
$12,142.86/yr
After 10yr DRIP, annual income (after tax)
$6,991,262.12/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, AVRO beats the other by $6,980,347.50/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AVRO + EPRT for your $10,000?

AVRO: 50%EPRT: 50%
100% EPRT50/50100% AVRO
Portfolio after 10yr
$9.81M
Annual income
$4,118,927.49/yr
Blended yield
42.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

AVRO
Analyst Ratings
4
Buy
6
Hold
Consensus: Hold
Altman Z
-0.7
Piotroski
4/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AVRO buys
0
EPRT buys
0
No recent congressional trades found for AVRO or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAVROEPRT
Forward yield142.86%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$19.55M$63.4K
Annual income after 10y$8,225,014.26$12,840.73
Total dividends collected$18.03M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy

Year-by-year: AVRO vs EPRT ($10,000, DRIP)

YearAVRO PortfolioAVRO Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$24,986$14,285.71$11,205$505.18+$13.8KAVRO
2$60,093$33,358.76$12,672$682.46+$47.4KAVRO
3$139,283$74,982.82$14,490$930.48+$124.8KAVRO
4$311,456$162,423.26$16,786$1,282.69+$294.7KAVRO
5$672,698$339,440.31$19,753$1,791.56+$652.9KAVRO
6$1,404,965$685,177.81$23,677$2,541.64+$1.38MAVRO
7$2,840,723$1,337,410.52$29,008$3,672.99+$2.81MAVRO
8$5,566,801$2,527,227.75$36,463$5,425.08+$5.53MAVRO
9$10,584,947$4,628,469.98$47,238$8,221.57+$10.54MAVRO
10$19,550,908$8,225,014.26$63,385$12,840.73+$19.49MAVRO

AVRO vs EPRT: Complete Analysis 2026

AVROStock

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Full AVRO Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this AVRO vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AVRO vs SCHDAVRO vs JEPIAVRO vs OAVRO vs KOAVRO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.